基础医学与临床 ›› 2010, Vol. 30 ›› Issue (11): 1172-1176.

• 研究论文 • 上一篇    下一篇

hTPO和hNIS共转染提高人胶质瘤、肺癌及甲状腺癌细胞摄碘能力

李玮 谭建 龙雷   

  1. 天津医科大学总医院核医学科 天津医科大学总医院
  • 收稿日期:2010-02-24 修回日期:2010-03-23 出版日期:2010-11-05 发布日期:2010-11-05
  • 通讯作者: 谭建

Increase of Radioiodide uptake by co- transfered the human sodium/iodide symporter and the human thyroperoxidase gene into glioma tumor,lung cancer and thyroid cancer cell lines

Wei LI, Jian TAN, Lei LONG   

  1. Tianjin Medical University General Hospital Tianjin Medical University General Hospital
  • Received:2010-02-24 Revised:2010-03-23 Online:2010-11-05 Published:2010-11-05
  • Contact: Jian TAN,

摘要: 目的 研究共转染人甲状腺过氧化物酶基因(hTPO)及人钠碘转运体基因(hNIS)后胶质瘤、肺癌及甲状腺癌细胞的摄碘能力变化。方法 克隆,重组,包装并扩增纯化得到重组腺病毒(AdTPO),测定病毒滴度。使用脂质体转染法将hNIS基因转染入人胶质瘤、肺癌及甲状腺癌细胞系中,经过G418抗生素筛选获得稳定表达hNIS的细胞系,只转染hNIS基因的细胞系为对照组;使用重组腺病毒将hTPO基因转导入对照组中,共转染hNIS及hTPO基因的细胞系为实验组;未转入hTPO和hNIS基因的原始肿瘤细胞系为空白对照组。然后进行3组细胞系的体外摄125I 率及各细胞系的125I外流实验。结果 在各肿瘤细胞系中,实验组细胞的摄碘率和有效半衰期,较对照组细胞和空白对照组细胞均有所提高,实验组细胞的摄碘率:H460组为59628 1281,U251组为7968 1261,ARO组为52971 2162,FRO组为49638 1281,三组间总体具有统计学差异(P<0.01)。结论 将hTPO和hNIS基因共转染至肿瘤后,能有效提高肿瘤的摄碘能力并延长细胞内碘滞留时间。

关键词: 钠/碘同向转运体, 甲状腺过氧化物酶, 基因治疗, 放射性核素治疗, 重组腺病毒

Abstract: Objective The aim of this study is to investigated the iodide uptake ability of iodide in glioma tumor,lung cancer and thyroid cancer cell lines after co- transfered the human sodium/iodide symporter and the human thyroperoxidase gene. Methods Through cloning, recombination, packaging and amplifying, the recombinant adenosine virus AdTPO was constructed. After purification. After transfected hNIS gene into tumor cell lines through liposome, stably expressing hNIS gene cell lines selected by G418 antibiotics was determined as control group. Using AdTPO, hTPO gene was transducted into control group cell lines, as experimental group. Tumor cell lines without hTPO and hNIS gene was applied as blank control group. Then, we investigated the 125I uptake assay and 125I influx experiments with glioma tumor,lung cancer and thyroid cancer cell lines. Results We were successful in co-transfecting hNIS and hTPO gene into human tumor cell lines, 125I uptakes and effective half life in experimental group was linger than control groups cell lines .After co-transfecting hNIS and hTPO gene, the uptake ability of 125I was 59628 1281,79638 1261,52971 2162and 49638 1281 counts·min-1 in H460, U251, ARO and FRO tumor cell lines. Conclusion The uptake ability of 125I could increase by co-transfection with hNIS and hTPO genes into human tumor cell lines.

Key words: Human sodium/ iodide symporter, Thyroperoxidase, Gene therapy, Radionuclide therapy, Recombinant adenovirus